Mekonos Raises $4.6M – New Capital & Expertise Will Accelerate Development of the Company’s Chip (SoC) & Commercial Partnerships

November 23, 2020

Mekonos, a biotech company launching the first-of-its-kind system-on-a-chip (SoC) for targeted ex vivo gene engineering, today announced it has completed a $4.6 million financing round.

Mekonos will use the new capital to accelerate the SoC platform for its current and new commercial partnerships. The SoC platform, with IP from Stanford University, is a breakthrough that allows for molecular delivery in gene editing and synthetic biology. The platform is scalable across all cell types and has shown to be a high yield solution for partners. The platform helps companies increase capacity, accelerate discoveries, and develop new pre-clinical assets in the emerging cell and gene therapy space.

The financing round was led by Novartis AG with participation from institutional VCs including Hike Ventures, CRCM Ventures. Existing investors participated in the round, including Good AI Capital and previous lead Elementum Ventures.

“We are delighted to work with such a strong team of investors and advisors who share our vision for the future of molecular delivery, gene therapies, and synthetic biology. This financing follows exciting momentum from the past year, including ongoing collaborations with two top 5 pharma companies and cell therapy research groups for our high yield SoC molecular delivery,” said Anil Narasimha, Ph.D., Co-Founder and CEO, Mekonos.

The company recently completed pilots with key top pharmaceutical companies and research institutes that demonstrated high efficacy of modified gene expression and cell viability. They are now preparing to expand existing partnerships and engage in new ones.

Mekonos’ platform is a physically controlled infrastructure that removes statistical uncertainty so that therapy cells are controlled like data. A scalable gene-editing chip constitutes the core of such a platform. Thanks to the recent combination of commercialized innovations, the vision of applying advanced semiconductor manufacturing technology to the production of disposable chips capable of editing the genes of millions of cells in parallel would have been unthinkable a few years ago. Bringing such scale to the application space of advanced therapies would allow for an unmatched level of automation, quality, precision, and agility from other existing technologies.

“The Mekonos technology represents a highly innovative non-viral gene delivery method that can benefit all cell therapy modalities,” said Dr. Cassian Yee, Director of Solid Tumor Cell Therapy, who recently joined Dr. Carolyn Bertozzi, Director, ChEM-H, and Dr. Irv Weissman, Director, Institute for Stem Cell Biology and Regenerative Medicine on the scientific advisory board of the company.

Medical Device News Magazine
Medical Device News Magazine provides our readership with breaking medical device / biotechnology news. Our subscribers include medical specialists, device industry executives, investors, and other allied health professionals, as well as patients who are interested in researching various medical devices. We hope you find value in our easy-to-read publication and its overall objectives! Medical Device News Magazine is a division of PTM Healthcare Marketing, Inc. Pauline T. Mayer is the managing editor.

More News!

MMI notes the funds will support commercialization of the Symani® Surgical System in high-growth markets and continued investment in studies that generate clinical evidence and enable indication expansion. Investments will also accelerate advanced technology capabilities and enable MMI to scale its operational capabilities globally.
“We are excited to begin our journey as a public company with this additional investment. We believe Tevogen’s patient-centric approach, which merges a focus on affordability with advanced science, is a blueprint for sustainable success in the current era of healthcare. I am pleased that investors now have the opportunity to participate in Tevogen’s mission to become the very first life science company offering commercially attractive and affordable personalized T cell therapies for large patient populations in virology, oncology, and neurology, said the CEO of Tevogen Bio.
MB2 Dental notes the financing will be used to fund upcoming acquisitions and future growth for the company, following a record year of growth in 2023 with 150 new partnerships.
Procyrion notes the funding will support the DRAIN-HF pivotal IDE trial evaluating the company's Aortix pump, internal R&D programs to improve manufacturability, and commercialization preparation.
PhotoniCare, in January of this year, announced that the U.S. Food and Drug Administration had granted clearance for its TOMi™ Scope for non-invasive imaging of the middle ear.

By using this website you agree to accept Medical Device News Magazine Privacy Policy